Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The development of myelin repair agents for treatment of multiple sclerosis: Progress and challenges.
New drug for relapsing multiple sclerosis.
The role of kinin B1 and B2 receptors in the persistent pain induced by experimental autoimmune encephalomyelitis (EAE) in mice: Evidence for the involvement of astrocytes.
The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
EXPRESSION OF CONCERN: The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Inflammatory demyelinating diseases in children: an update.
Role of vitamin D in acquired immune and autoimmune diseases.
Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis.
[Immunomodulatory properties of stem mesenchymal cells in autoimmune diseases.]
The prevalence of familial multiple sclerosis in saskatoon, Saskatchewan.
Mode of action and clinical studies with alemtuzumab.
[Diet and multiple sclerosis].
Few patients with neurodegenerative disorders require spinal surgery.
Lipopolysaccharide treatment arrests the cell cycle of BV-2 microglial cells in G1 phase and protects them from UV light-induced apoptosis.
Mast cells on the mind: new insights and opportunities.
[Multiple sclerosis.]
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.
Evidence for a multiple sclerosis epidemic?
Goal attainment in cognitive rehabilitation in MS patients.
EBNA2 Binds to Genomic Intervals Associated with Multiple Sclerosis and Overlaps with Vitamin D Receptor Occupancy.
Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review.
Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis.
Acute disseminated encephalomyelitis presenting as pyrexia of unknown origin.
Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis.
Association between neuromyelitis optica and tuberculosis in a Chinese population.
Pages
« first
‹ previous
…
375
376
377
378
379
380
381
382
383
…
next ›
last »